ArticleNPJ digital medicine2026
A robust vision language model for molecular status prediction and radiology report generation in adult-type diffuse gliomas.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness, Safety, and Workflow Burden of Large Language Model-Based Medical Report Generation: Systematic Review.Journal of medical Internet research · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to establish a robust vision-language model ("Glio-LLaMA-Vision") for molecular status prediction and radiology report generation (RRG) in adult-type diffuse gliomas. Multiparametric MRI data and paired radiology reports from 1001 patients with adult-type diffuse gliomas were included in the institutional training set. A vision-language model, Glio-LLaMA-Vision, was developed from LLaMA 3.1 pre-trained on 2.79 million biomedical image-text pairs from PubMed Central and further fine-tuned from the institutional training set. The performance was validated in 100 patients and 75 patients with paired MRI-radiology reports from an institutional validation set and another tertiary institution (AMC), and in 170 and 477 patients with MRI from TCGA and UCSF datasets, respectively. In terms of IDH mutation status prediction, Glio-LLaMA-Vision showed AUCs ranging from 0.85-0.95 in the internal validation and external datasets. In terms of RRG, the BLEU-1 and ROUGE-L scores were 0.50 and 0.49 in the internal validation, respectively, and 0.32 and 0.36 on the AMC dataset, respectively. Overall, 37.8% of generated reports were considered superior or equal to the original reports, while 91.0% of generated reports were considered clinically acceptable by neuroradiologists. In conclusion, Glio-LLaMA-Vision demonstrates promising performance in molecular status prediction and RRG in adult-type diffuse gliomas, showing potential for clinical assistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.